Showing 5,874 results

Filters Content type: News, Editors' picks Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

New & experimental HIV treatments

Gilead’s investigational tenofovir alafenamide (TAF)-based single tablet HIV regimen meets 48-week primary objective in two Phase 3 studies

Editor's pick
Gilead press release
25 September 2014
New & experimental HIV treatments

Gilead's Latest HIV Pill Meets Study Goals

Editor's pick
Wall Street Journal
24 September 2014
Bad science & bogus treatments

HIV Research Fraud Highlights Scramble for Federal Science Grant Money

Editor's pick
Science Speaks
24 September 2014
Government, leadership & policy

Has Jacob Zuma hurt the fight against AIDS more than Thabo Mbeki?

Editor's pick
Africa Check
23 September 2014
New & experimental HIV treatments

Gilead Sciences: A Preview of Important HIV Drug Study Results

Editor's pick
The Street
23 September 2014
Kidney problems

Guidelines Advise Against Tenofovir for HIV Patients With Kidney Disease

Editor's pick
The Body Pro
22 September 2014
Adherence

Stigma, ambivalence and other priorities – explaining poor adherence to PrEP and vaginal microbicides

News
19 September 2014
New & experimental HIV treatments

PREZCOBIX™ now available for Canadians living with HIV

Editor's pick
Newswire.ca
18 September 2014
HIV treatment

CDC Launches HIV Treatment Awareness Campaign

Editor's pick
Poz
17 September 2014
New & experimental HIV treatments

First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks

Editor's pick
NATAP
16 September 2014
Side effects

Switch From Efavirenz to Rilpivirine Quells CNS Toxicity, Improves Sleep

Editor's pick
NATAP
16 September 2014
Chemsex & recreational drug use

Drug use strongly associated with sex, condomless sex and STIs in gay men living with HIV in England

News
16 September 2014
New & experimental HIV treatments

Long acting HIV drugs to be developed

Editor's pick
University of Liverpool press release
15 September 2014
PEP

Change to recommended regimen for post-exposure prophylaxis (PEP)

Editor's pick
Expert Advisory Group on AIDS (EAGA)
11 September 2014
New & experimental HIV treatments

New medicines in development give hope to patients with HIV/AIDS

Editor's pick
Pharmaceutical Research and Manufacturers of America
11 September 2014
Pregnancy and vertical transmission

Pregnant women need more support on looking after their own health after childbirth – could help retention in Option B+ programmes

News
10 September 2014
New & experimental HIV treatments

New HIV Drug, BMS-986001, Safe and Effective in Treatment-Naive Patients

Editor's pick
The Body
10 September 2014
New & experimental HIV treatments

Drug-level study shows feasibility of long-acting integrase inhibitor cabotegravir

Editor's pick
HIVand hepatitis.com
10 September 2014
Treatment outcomes & life expectancy

After two years on antiretroviral therapy, survival in South African patients meets rates from North America

Editor's pick
Science Daily
10 September 2014
Adherence

Uganda: Aids Patients Reject Bitter ARVs

Editor's pick
Allafrica.com
10 September 2014
Side effects

New Tenofovir Alafenamide Combo Pill Has Less Effect on Kidneys and Bones

Editor's pick
HIVandhepatitis.com
9 September 2014
Resistance

Longer time to virological failure and less drug resistance seen in people taking Atripla than in people taking separate drugs

News
9 September 2014
Economic & social inequality

Social inequalities associated with late HIV diagnosis and delayed HIV treatment – European study

News
5 September 2014
New & experimental HIV treatments

EU marketing authorization for ViiV Healthcare HIV drug Triumeq

Editor's pick
Pharma Letter
4 September 2014